These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 27296257)

  • 41. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
    Musanovic A; Trnacevic S; Mekic M; Musanovic A
    Med Arch; 2013; 67(5):361-4. PubMed ID: 24601173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
    Nguyen TV
    Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
    Stancu S; Bârsan L; Stanciu A; Mircescu G
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
    Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
    Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure.
    Tilkian EE; Tzekov VD; Pandeva SM; Kumchev EP; Nikolov DG; Dimitrakov JD; Dimitrakov DD
    Folia Med (Plovdiv); 2000; 42(3):11-5. PubMed ID: 11347329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
    Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
    Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
    J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
    Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
    Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
    Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
    Mukhin NA; Milovanova LY; Fomin VV; Kozlovskaya LV; Taranova MV; Androsova TV; Borisov AA
    Klin Med (Mosk); 2017; 95(3):272-7. PubMed ID: 30303650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
    Adhikary L; Acharya S
    JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency.
    Gasché C; Reinisch W; Lochs H; Parsaei B; Bakos S; Wyatt J; Fueger GF; Gangl A
    Dig Dis Sci; 1994 Sep; 39(9):1930-4. PubMed ID: 8082499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.